Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1042) 1042
Book Chapter (30) 30
Book / eBook (6) 6
Book Review (2) 2
Dissertation (2) 2
Newspaper Article (2) 2
Magazine Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (812) 812
humans (712) 712
life sciences & biomedicine (705) 705
animals (330) 330
male (308) 308
female (301) 301
macrocyclic compounds - therapeutic use (253) 253
pharmacology & pharmacy (229) 229
antiviral agents - therapeutic use (215) 215
drug therapy, combination (193) 193
hepatitis c, chronic - drug therapy (192) 192
middle aged (188) 188
lactams, macrocyclic - pharmacology (184) 184
hsp90 heat-shock proteins - antagonists & inhibitors (182) 182
carbamates - therapeutic use (181) 181
benzoquinones - pharmacology (175) 175
mice (157) 157
macrocyclic compounds - chemistry (153) 153
oncology (153) 153
uracil - analogs & derivatives (150) 150
biological and medical sciences (149) 149
sulfonamides - therapeutic use (146) 146
anilides - therapeutic use (145) 145
hepacivirus - genetics (145) 145
chemistry (141) 141
hepatitis c (141) 141
heat shock proteins (139) 139
cell line, tumor (134) 134
hepatitis c virus (134) 134
aged (132) 132
adult (131) 131
biochemistry & molecular biology (131) 131
genotype (129) 129
medical sciences (129) 129
ritonavir - therapeutic use (127) 127
treatment outcome (127) 127
physical sciences (121) 121
macrocyclic compounds - pharmacology (119) 119
proteins (116) 116
hsp90 heat-shock proteins - metabolism (113) 113
cancer (112) 112
analysis (110) 110
uracil - therapeutic use (107) 107
health aspects (100) 100
antineoplastic agents - pharmacology (97) 97
macrocyclic compounds (97) 97
gastroenterology & hepatology (95) 95
hepacivirus - drug effects (95) 95
macrocyclic compounds - administration & dosage (94) 94
ribavirin - therapeutic use (94) 94
care and treatment (93) 93
hepatitis (92) 92
pharmacology. drug treatments (91) 91
lactams, macrocyclic (89) 89
lactams, macrocyclic - therapeutic use (88) 88
antiviral agents (87) 87
sustained virologic response (85) 85
research (84) 84
benzoquinones (81) 81
macrocyclic compounds - adverse effects (81) 81
ritonavir (81) 81
antiviral agents - administration & dosage (78) 78
antiviral agents - adverse effects (77) 77
chemistry, multidisciplinary (75) 75
geldanamycin (75) 75
hepatitis c - drug therapy (74) 74
apoptosis - drug effects (73) 73
antineoplastic agents - therapeutic use (72) 72
ribavirin (72) 72
apoptosis (71) 71
carbamates - administration & dosage (71) 71
drug therapy (69) 69
tumors (69) 69
carbamates - adverse effects (68) 68
chemistry, medicinal (67) 67
hepatitis c, chronic - virology (66) 66
interferon (66) 66
benzoquinones - therapeutic use (65) 65
infectious diseases (65) 65
antineoplastic agents (64) 64
genetic aspects (62) 62
patients (62) 62
cell proliferation - drug effects (61) 61
liver (59) 59
peptides (59) 59
molecular structure (58) 58
sulfonamides - administration & dosage (58) 58
cell biology (57) 57
hsp90 (57) 57
research article (57) 57
anilides - administration & dosage (56) 56
anilides - adverse effects (56) 56
clinical trials (56) 56
infections (56) 56
sulfonamides - adverse effects (56) 56
ritonavir - administration & dosage (55) 55
sofosbuvir - therapeutic use (55) 55
dose-response relationship, drug (54) 54
pharmacology (54) 54
drug combinations (53) 53
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1075) 1075
German (9) 9
Chinese (4) 4
Japanese (4) 4
Spanish (4) 4
Czech (2) 2
French (2) 2
Hungarian (2) 2
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectives
by Asselah, Tarik and Boyer, Nathalie and Saadoun, David and Martinot‐Peignoux, Michele and Marcellin, Patrick
Liver international, ISSN 1478-3223, 01/2016, Volume 36, Issue S1, pp. 47 - 57
ledipasvir | sofosbuvir | dasabuvir grazoprevir | ombitasvir | velpatasvir | elbasvir | paritaprevir | Ombitasvir | Dasabuvir grazoprevir | Ledipasvir | Paritaprevir | Elbasvir | Velpatasvir | Sofosbuvir | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Sofosbuvir - therapeutic use | Anilides - therapeutic use | Benzofurans - therapeutic use | Antiviral Agents - therapeutic use | Humans | Fluorenes - therapeutic use | Cyclopropanes | Hepacivirus - genetics | Uracil - therapeutic use | Amides | Genotype | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Sulfonamides - therapeutic use | Female | Imidazoles - therapeutic use | Carbamates - therapeutic use | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Uracil - analogs & derivatives | Virus diseases | Protease inhibitors | Proteases | Interferon | Drug therapy | Hepatitis C virus | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
by Jacobson, Ira M and Lawitz, Eric and Gane, Edward J and Willems, Bernard E and Ruane, Peter J and Nahass, Ronald G and Borgia, Sergio M and Shafran, Stephen D and Workowski, Kimberly A and Pearlman, Brian and Hyland, Robert H and Stamm, Luisa M and Svarovskaia, Evguenia and Dvory-Sobol, Hadas and Zhu, Yanni and Subramanian, G. Mani and Brainard, Diana M and McHutchison, John G and Bräu, Norbert and Berg, Thomas and Agarwal, Kosh and Bhandari, Bal Raj and Davis, Mitchell and Feld, Jordan J and Dore, Gregory J and Stedman, Catherine A.M and Thompson, Alexander J and Asselah, Tarik and Roberts, Stuart K and Foster, Graham R
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2017, Volume 153, Issue 1, pp. 113 - 122
Gastroenterology and Hepatology | Direct-Acting Antiviral Agent | Shortened Duration Therapy | Clinical Trial | Comparison | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Humans | Middle Aged | Male | Carbamates - administration & dosage | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Drug Therapy, Combination | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Macrocyclic Compounds - therapeutic use | Sofosbuvir - administration & dosage | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Sulfonamides - administration & dosage | Medical colleges | Care and treatment | Protease inhibitors | Proteases | Transplantation of organs, tissues, etc | Product development | Hepatitis C virus | Hepatitis C | Health aspects | Analysis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
by Bourlière, Marc and Gordon, Stuart C and Flamm, Steven L and Cooper, Curtis L and Ramji, Alnoor and Tong, Myron and Ravendhran, Natarajan and Vierling, John M and Tran, Tram T and Pianko, Stephen and Bansal, Meena B and de Lédinghen, Victor and Hyland, Robert H and Stamm, Luisa M and Dvory-Sobol, Hadas and Svarovskaia, Evguenia and Zhang, Jie and Huang, K.C and Subramanian, G. Mani and Brainard, Diana M and McHutchison, John G and Verna, Elizabeth C and Buggisch, Peter and Landis, Charles S and Younes, Ziad H and Curry, Michael P and Strasser, Simone I and Schiff, Eugene R and Reddy, K. Rajender and Manns, Michael P and Kowdley, Kris V and Zeuzem, Stefan and POLARIS-1 and POLARIS-4 Investigators and POLARIS-1 and POLARIS-4 Investigators
The New England journal of medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hepatitis C - drug therapy | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Hepatitis C - complications | Sofosbuvir - adverse effects | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Hepatitis C - virology | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Care and treatment | Hepatitis C virus | Drug therapy | Patients | Health aspects | Headache | Antiretroviral drugs | Antiviral agents | Proteinase | Clinical trials | Diarrhea | Fatigue | Nausea | Cirrhosis | Hepatitis | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study
by Evon, Donna M and Sarkar, Souvik and Amador, Jipcy and Lok, Anna S and Sterling, Richard K and Stewart, Paul W and Reeve, Bryce B and Serper, Marina and Reau, Nancy and Rajender Reddy, K and Di Bisceglie, Adrian M and Nelson, David R and Golin, Carol E and Lim, Joseph K and Fried, Michael W
Journal of hepatology, ISSN 0168-8278, 09/2019, Volume 71, Issue 3, pp. 486 - 497
Treatment | Sleep | Pain | Liver | Patient-reported outcome | HCV | PRO | Symptom | Quality of life | Functioning | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Benzimidazoles | Prospective Studies | Humans | Middle Aged | Fluorenes | Hepatitis C, Chronic - virology | Male | Cyclopropanes - therapeutic use | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Ritonavir - therapeutic use | Adult | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Patient Reported Outcome Measures | Quinoxalines - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Benzofurans - therapeutic use | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Amides - therapeutic use | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Aged | Sustained Virologic Response | Carbamates - therapeutic use | Uracil - analogs & derivatives | Mental disorders | Ritonavir | Mental health | Chronic infection | Fatigue | Regression analysis | Patients | Cirrhosis | Hepatitis | Minimum inhibitory concentration | Hepatitis C | Index Medicus | sleep | treatment | functioning | pain | symptom | liver | patient-reported outcome | quality of life
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
by Feld, Jordan J and Kowdley, Kris V and Coakley, Eoin and Sigal, Samuel and Nelson, David R and Crawford, Darrell and Weiland, Ola and Aguilar, Humberto and Xiong, Junyuan and Pilot-Matias, Tami and DaSilva-Tillmann, Barbara and Larsen, Lois and Podsadecki, Thomas and Bernstein, Barry
The New England journal of medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | Biological and medical sciences | General aspects | Medical sciences | Pharmacology. Drug treatments | Antibiotics. Antiinfectious agents. Antiparasitic agents | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
by Zeuzem, Stefan and Jacobson, Ira M and Baykal, Tolga and Marinho, Rui T and Poordad, Fred and Bourlière, Marc and Sulkowski, Mark S and Wedemeyer, Heiner and Tam, Edward and Desmond, Paul and Jensen, Donald M and Di Bisceglie, Adrian M and Varunok, Peter and Hassanein, Tarek and Xiong, Junyuan and Pilot-Matias, Tami and DaSilva-Tillmann, Barbara and Larsen, Lois and Podsadecki, Thomas and Bernstein, Barry
The New England journal of medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | Biological and medical sciences | General aspects | Medical sciences | Pharmacology. Drug treatments | Antibiotics. Antiinfectious agents. Antiparasitic agents | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | RNA, Viral - isolation & purification | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Retreatment | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Ritonavir | Infections | RNA polymerase | Pruritus | Patients | Ribavirin | Cirrhosis | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Novel molecular targeted therapies for refractory thyroid cancer
by Perez, Cesar A and Santos, Edgardo S and Arango, Belisario A and Raez, Luis E and Cohen, Ezra E. W and Eisele, David W
Head & neck, ISSN 1043-3074, 05/2012, Volume 34, Issue 5, pp. 736 - 745
epidermal growth factor (EGF) | RET | immunomodulator | vascular disrupting agent | multi‐kinase inhibitor | vascular endothelial growth factor (VEGF) | thyroid cancer | histone acetylation | B‐Raf | heat shock protein (HSP) | multi-kinase inhibitor | B-Raf | Otorhinolaryngology | Life Sciences & Biomedicine | Surgery | Science & Technology | Otorhinolaryngology. Stomatology | Malignant tumors | Pharmacology. Drug treatments | Thyroid. Thyroid axis (diseases) | Biological and medical sciences | Endocrinopathies | Medical sciences | Immunomodulators | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bibenzyls - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Proto-Oncogene Proteins c-kit - antagonists & inhibitors | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Valproic Acid - therapeutic use | Depsipeptides - therapeutic use | Imidazoles - therapeutic use | Lactams, Macrocyclic - therapeutic use | Pyrroles - therapeutic use | Pyridines - therapeutic use | Bortezomib | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Piperazines - therapeutic use | Imatinib Mesylate | Sulfonamides - therapeutic use | Thyroid Neoplasms - drug therapy | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Quinolines - therapeutic use | Benzamides | Thalidomide - therapeutic use | Benzoquinones - therapeutic use | Indazoles - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
by Andreone, Pietro and Colombo, Massimo G and Enejosa, Jeffrey V and Koksal, Iftihar and Ferenci, Peter and Maieron, Andreas and Müllhaupt, Beat and Horsmans, Yves and Weiland, Ola and Reesink, Henk W and Rodrigues, Lino and Hu, Yiran B and Podsadecki, Thomas and Bernstein, Barry
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights